[go: up one dir, main page]

ATE287260T1 - Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung - Google Patents

Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung

Info

Publication number
ATE287260T1
ATE287260T1 AT96918078T AT96918078T ATE287260T1 AT E287260 T1 ATE287260 T1 AT E287260T1 AT 96918078 T AT96918078 T AT 96918078T AT 96918078 T AT96918078 T AT 96918078T AT E287260 T1 ATE287260 T1 AT E287260T1
Authority
AT
Austria
Prior art keywords
controlled release
formulation
tablet
preformed opening
passageway
Prior art date
Application number
AT96918078T
Other languages
English (en)
Inventor
Chih-Ming Chen
Der-Yang Lee
Jianbo Xie
Aurelio Rodriguez
Original Assignee
Andrx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Pharmaceuticals Inc filed Critical Andrx Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE287260T1 publication Critical patent/ATE287260T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
AT96918078T 1995-06-07 1996-06-05 Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung ATE287260T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/476,455 US5654005A (en) 1995-06-07 1995-06-07 Controlled release formulation having a preformed passageway
PCT/US1996/008869 WO1996040080A1 (en) 1995-06-07 1996-06-05 Controlled release formulation having a preformed passageway

Publications (1)

Publication Number Publication Date
ATE287260T1 true ATE287260T1 (de) 2005-02-15

Family

ID=23891918

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96918078T ATE287260T1 (de) 1995-06-07 1996-06-05 Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung

Country Status (8)

Country Link
US (1) US5654005A (de)
EP (1) EP0835102B1 (de)
JP (1) JPH11506774A (de)
AT (1) ATE287260T1 (de)
AU (1) AU710110B2 (de)
DE (1) DE69634204T2 (de)
NZ (1) NZ310099A (de)
WO (1) WO1996040080A1 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348469B1 (en) 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US6048547A (en) * 1996-04-15 2000-04-11 Seth; Pawan Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient
GB9609094D0 (en) * 1996-05-01 1996-07-03 Univ Strathclyde Delivery device
EP0811374A1 (de) 1996-05-29 1997-12-10 Pfizer Inc. Formulierung für ein Kombinationspräparat mit Cetirizin und Pseudoephedrin
DE69735002T2 (de) * 1996-10-25 2006-10-26 Shire Laboratories, Inc. Osmotisches Verabreichungssystem für lösliche Dosen
US6361796B1 (en) * 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
DE19729273C2 (de) * 1997-07-09 2000-08-17 Aventis Res & Tech Gmbh & Co Thermoplastische Mischung auf 1,4-alpha-D-Polyglucanbasis, Verfahren zu deren Herstellung und Verwendung
TR200000752T2 (tr) 1997-09-25 2000-09-21 Bayer Aktiengesellschaft Etkin terkibin kontrollü salınımı için ilaç formülü.
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
WO2000025757A1 (en) * 1998-10-29 2000-05-11 Merck & Co., Inc. Sustained release delivery of highly water-soluble compounds
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
DE60042352D1 (de) * 1999-02-10 2009-07-23 Pfizer Prod Inc Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
CA2378829A1 (en) * 1999-07-20 2001-01-25 Merck & Co., Inc. Sustained release drug dispersion delivery device
JP2003520759A (ja) * 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド 単位核を有する徐放性錠剤
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
WO2001047498A2 (en) 1999-12-23 2001-07-05 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
EE200200361A (et) * 1999-12-23 2003-10-15 Pfizer Products Inc. Hüdrogeeli-juhitav ravimi doseerimise vahend
EP1239835B1 (de) 1999-12-23 2013-03-20 Bend Research, Inc. Arzneizusammensetzung mit erhöhter arzneistoffkonzentration
US6248359B1 (en) 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
PT1251832E (pt) 2000-02-04 2007-01-31 Depomed Inc Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
US6270797B1 (en) * 2000-05-18 2001-08-07 Usv Limited Sustained release pharmaceutical composition containing glipizide and method for producing same
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
WO2002036077A2 (en) * 2000-11-06 2002-05-10 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
EP1372614A4 (de) * 2001-03-16 2007-10-31 Andrx Pharmaceuticals Llc Sulfonylharnstoff-formulierung mit kontrollierter freisetzung
KR20040018394A (ko) * 2001-07-04 2004-03-03 썬 파마슈티컬 인더스트리스 리미티드 위 정체 제어되는 약물 전달 계
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
EP1429745A2 (de) * 2001-09-28 2004-06-23 McNEIL-PPC, INC. Zusammengesetzte darreichungsformen mit einem eingelagerten anteil
KR20040081446A (ko) * 2002-01-04 2004-09-21 아이박스 리서치, 인코포레이티드 글리피지드의 서방성을 위한 약물 전달 체계
JP2005522424A (ja) 2002-02-01 2005-07-28 ファイザー・プロダクツ・インク コレステリルエステル転移タンパク質インヒビターの制御放出性薬剤投与形態
TW200302748A (en) * 2002-02-01 2003-08-16 Pfizer Prod Inc Osmotic delivery system
KR100453288B1 (ko) * 2002-03-12 2004-10-21 한국화학연구원 약물의 제어 방출을 위한 스퀴즈-유형의 삼투성 약물 전달장치
CA2487786A1 (en) * 2002-05-31 2003-12-11 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US20040052844A1 (en) * 2002-09-16 2004-03-18 Fang-Hsiung Hsiao Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
US7988993B2 (en) * 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
US8293799B2 (en) * 2003-12-29 2012-10-23 Osmotica Keresleedelmo és Szolgáltató KFT Osmotic device containing a venlafaxine salt and a salt having an ion in common
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
US20040241252A1 (en) * 2003-05-29 2004-12-02 Abney Christopher Charles Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same
SI1575565T1 (sl) * 2003-08-08 2010-04-30 Biovail Lab Int Srl Tableta bupropion hidroklorida z modificiranim sprošŽŤanjem
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
KR100574554B1 (ko) * 2004-05-28 2006-04-27 한미약품 주식회사 니아신의 경구투여용 서방성 조성물
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
US20070036843A1 (en) * 2005-01-28 2007-02-15 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
KR100678421B1 (ko) * 2005-02-11 2007-02-02 주식회사 씨티씨바이오 염산 탐스로신 함유 방출조절 제제
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
AU2006269225B2 (en) * 2005-07-07 2011-10-06 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
CN102716490A (zh) * 2005-09-01 2012-10-10 卫材R&D管理有限公司 药物组合物的崩解性的改善方法
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
US20080241240A1 (en) * 2006-08-24 2008-10-02 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
GB0702974D0 (en) * 2007-02-15 2007-03-28 Jagotec Ag Method and apparatus for producing a tablet
EP2074993A1 (de) 2007-12-19 2009-07-01 Biovail Laboratories International S.r.l. Venlafaxin enthaltende Filmtabletten mit modifizierter Wirkstofffreisetzung
AU2008359725A1 (en) * 2008-07-24 2010-01-28 Handa Pharmaceuticals, Llc Stabilized atypical antipsychotic formulation
US20100285125A1 (en) * 2009-05-07 2010-11-11 Padma Venkitachalam Devarajan Delivery system for poorly soluble drugs
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
ES2569925T3 (es) 2009-09-30 2016-05-13 Acura Pharmaceuticals, Inc. Métodos y composiciones de disuasión del abuso
CN104873455B (zh) 2010-12-22 2023-09-12 普渡制药公司 包覆的抗篡改控制释放剂型
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
MX347961B (es) * 2011-09-16 2017-05-19 Purdue Pharma Lp Formulaciones de liberación inmediata resistentes a alteración.
EP3446685A1 (de) 2012-11-30 2019-02-27 Acura Pharmaceuticals, Inc. Selbstregulierende freisetzung eines pharmazeutischen wirkstoffs
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
SG11201506064UA (en) 2013-02-05 2015-08-28 Purdue Pharma Lp Tamper resistant pharmaceutical formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
US9616029B2 (en) 2014-03-26 2017-04-11 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
CN106660964B (zh) 2014-08-28 2021-09-03 卫材R&D管理有限公司 高纯度喹啉衍生物及其生产方法
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
AU2016309356B2 (en) 2015-08-20 2021-06-24 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
MX380144B (es) 2017-02-08 2025-03-12 Eisai R&D Man Co Ltd Composicion farmaceutica de tratamiento de tumores.
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
US20220378707A1 (en) * 2019-11-14 2022-12-01 Pfizer Inc. 1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3279470D1 (en) * 1981-04-03 1989-04-06 Fujisawa Pharmaceutical Co New cephem compounds, processes for their preparation, pharmaceutical compositions containing them and their starting compounds
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
JPH075457B2 (ja) * 1983-08-16 1995-01-25 ザ ウエルカム フアウンデ−シヨン リミテツド 調節された方法による有効成分の放出を可能にする医薬組成物
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
ES2039287T3 (es) * 1987-01-14 1993-09-16 Ciba-Geigy Ag Procedimiento para la obtencion de un sistema terapeutico peroral para productos activos dificilmente solubles.
US4801461A (en) * 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
US4810502A (en) * 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5186942A (en) * 1989-01-30 1993-02-16 Alza Corporation Nicardipine therapy
AU621182B2 (en) * 1989-01-30 1992-03-05 Alza Corporation Dosage form for administering calcium antagonist
AU651721B2 (en) * 1991-04-30 1994-07-28 Fmc Corporation Taste-masked medicaments and their preparation
CA2085871C (en) * 1991-12-27 2002-05-07 Gerald S. Rork A controlled release drug dispersion delivery device

Also Published As

Publication number Publication date
AU710110B2 (en) 1999-09-16
EP0835102A1 (de) 1998-04-15
DE69634204T2 (de) 2006-01-12
EP0835102A4 (de) 2000-07-19
EP0835102B1 (de) 2005-01-19
AU6042796A (en) 1996-12-30
US5654005A (en) 1997-08-05
DE69634204D1 (de) 2005-02-24
JPH11506774A (ja) 1999-06-15
WO1996040080A1 (en) 1996-12-19
NZ310099A (en) 1999-09-29

Similar Documents

Publication Publication Date Title
ATE287260T1 (de) Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung
AU4989997A (en) Soluble form osmotic dose delivery system
EP0822809A4 (de) Formulierung mit gesteuerter freisetzung für wasserlöslische arzneistoffe, in der eine auslaböffnung in situ gebildet wird
ATE269709T1 (de) Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff
BR0114633A (pt) Formulações farmacêuticas com liberação retardada
IS4146A (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
WO2004108067A3 (en) Programmed drug delivery system
DE69630375D1 (de) Pharmazeutische dosierungsform zur freisetzung im colon
IL146818A0 (en) New formulation
ZA997727B (en) Pharmaceutical composition for application to mucosa.
GB9025372D0 (en) Pharmaceutical dosage forms
MY101593A (en) Sustained release preparation.
AP2001002237A0 (en) Hydrogel-driven drug dosage form.
FI924419A0 (fi) Ett osmotiskt doseringssystem foer frigoerande av laekemedel i vaetskeform.
DE69726179D1 (de) Pharmazeutische suspensionssysteme
AU2001291526A1 (en) Sustained release composition containing clarithromycin
MY125548A (en) Water soluble film for oral administration with instant wettability
CA2085871A1 (en) A controlled release drug dispersion delivery device
ATE251895T1 (de) Hydrophobe arzneistoffabgabesysteme
CA2000932A1 (en) Oral pharmaceutical controlled release multiple unit dosage form
WO1996040074A3 (en) Device for releasing aggregation-stabilized, biologically active agent
CA2223014A1 (en) Controlled release formulation having a preformed passageway
AR039314A1 (es) Formulaciones farmaceuticas de liberacion retrasada

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties